Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7114826 | 0.90 | TRPA1 (0.40) | TRPA1CNR2KMT2AMEN1HTT | |
| SCHEMBL7120749 | 0.84 | MAPT (0.46) | MAPTHTTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL7118303 | 0.84 | L3MBTL1 (0.41) | TRPA1MAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL7058428 | 0.83 | SMN1; SMN2 (0.44) | MAPTKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6791261 | 0.80 | TRPA1 (0.54) | TRPA1CNR2MAPTKMT2AMEN1 | |
| SCHEMBL7127312 | 0.77 | ALDH1A1 (0.49) | TRPA1CNR2MAPTKMT2AMEN1 | |
| SCHEMBL7059284 | 0.76 | PTGS1 (0.34) | L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7123266 | 0.74 | KDM4E (0.39) | CNR2MAPTKMT2AHTTALDH1A1 | |
| SCHEMBL6679666 | 0.74 | MTHFD2 (0.38) | MAPTALDH1A1LMNAKDM4E | |
| SCHEMBL7116975 | 0.74 | TP53 (0.35) | MAPTKMT2AL3MBTL1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | TRPA1 4726/4885CNR2 4567/4885MAPT 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.